Tonix Pharmaceuticals Advances TNX-4800 Monoclonal Antibody for Lyme Disease Prevention with FDA Meeting Planned for 2026
核心洞察
Tonix Pharmaceuticals (搜索) announced program updates for TNX-4800 (搜索), a long-acting monoclonal antibody designed for seasonal Lyme disease (搜索) prevention through a single annual subcutaneous injection.
The company plans to meet with the FDA in 2026 to explore Phase 2/3 development options, including a controlled human infection model study using Borrelia-infected ticks.
TNX-4800 (搜索) demonstrated 95% efficacy in preventing infection in non-human primates after 6 days of exposure to infected ticks, with serum concentrations remaining quantifiable for up to 12 months.
Tonix Pharmaceuticals (搜索) announced significant program updates for TNX-4800 (搜索), a long-acting human monoclonal antibody designed to provide seasonal protection against Lyme disease (搜索) through a single annual injection. The company plans to meet with the FDA in 2026 to explore Phase 2/3 development pathways, with investigational product expected to be available for clinical trials in early 2027.
Novel Mechanism of Action
TNX-4800 (搜索) targets the outer surface protein A (OspA (搜索)) of Borrelia burgdorferi, the causative agent of Lyme disease (搜索). Unlike traditional vaccines that rely on the recipient's immune system to generate antibodies, TNX-4800 provides direct passive immunity by delivering pre-formed antibodies.
"TNX-4800 (搜索) provides near-immediate immunity to the bacteria that cause Lyme disease (搜索) after a single administration, which is very different from Lyme disease vaccine programs currently in development," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals (搜索). "Prophylaxis with TNX-4800 may also avoid the limitations of vaccine products designed to actively immunize against Lyme, including suboptimal immune responses from age, immunocompetence, and other reasons."
The antibody works by binding to OspA (搜索) when TNX-4800 (搜索)-containing blood is ingested by ticks, killing and blocking the maturation of Borrelia burgdorferi in the tick's midgut, thereby preventing transmission to humans.
Promising Preclinical and Clinical Data
Published work in non-human primates demonstrated that TNX-4800 (搜索) was 95% effective in preventing infection after 6 days of exposure to ticks infected with Borrelia burgdorferi. The antibody was engineered with an extended half-life through amino acid substitutions in its crystallizable fragment (Fc) domain.
Clinical pharmacokinetic data from a randomized, double-blind, sequential dose-escalation study (NCT04863287) in 44 healthy adults showed promising durability. TNX-4800 (搜索) concentrations remained quantifiable for more than 200 days in 80% of volunteers at the lowest dose (0.5 mg/kg) and for up to 350 days in the majority of volunteers at higher doses (≥1.5 mg/kg). The mean half-life ranged from 62-69 days across dose groups, with serum concentrations remaining quantifiable for up to 12 months in most subjects.
Safety Profile and Development Strategy
The Phase 1 study demonstrated that TNX-4800 (搜索) was generally safe and well-tolerated. Anti-drug antibodies were detected in less than 10% of treated subjects, with no impact on pharmacokinetics. Most adverse events were mild or moderate, and mean exposure for the highest dose cohort (10 mg/kg) was less than 20% of the highest exposures observed in rat toxicology studies.
Tonix is exploring clinical development options including a controlled human infection model (CHIM) study using Borrelia-infected ticks that mimics natural infection. "We believe a controlled human infection model study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 (搜索) efficacy for approval," Lederman stated.
Addressing a Significant Unmet Medical Need
Lyme disease (搜索) remains the most common vector-borne infection in the United States, with incidence climbing each year. The disease occurs most commonly in the Northeast, mid-Atlantic, and upper-Midwest regions. Currently, there are no FDA-approved vaccines or prophylactics available to protect against Lyme disease.
Even with antibiotic treatment, up to 20% of cases may progress to Post-Treatment Lyme Disease Syndrome (搜索) (PTLDS), also called "Chronic Lyme (搜索)" or "Long Lyme," which is characterized by joint and muscle pain, fatigue, and other debilitating symptoms.
TNX-4800 (搜索)'s approach sidesteps the multidose schedules required for OspA (搜索) vaccines in development and avoids the autoimmunity concerns that led to the withdrawal of previously FDA-approved Lyme vaccines from the market.
Market Potential and Timeline
Approximately 70 million people who live, work, or vacation in areas of the U.S. where Lyme disease (搜索) is endemic could potentially benefit from pre-exposure prophylaxis with TNX-4800 (搜索). The single spring injection is designed to provide protection through the entire tick season.
Tonix expects to have investigational product produced under Good Manufacturing Practices (GMP) available for testing in early 2027. The company intends to advance TNX-4800 (搜索) through additional clinical trials with the goal of submitting a Biologics Licensing Application (BLA) to the FDA.
The monoclonal antibody prophylaxis approach has precedent, with two long-acting monoclonal antibody products having won FDA approval for prophylaxis against respiratory syncytial virus (RSV): AstraZeneca's Beyfortus (nirsevimab) and Merck (搜索)'s Enflonsia (搜索) (clesrovimab).